diet doctors – Page 2 – Diet Business Watch

Weight Watchers Streamlines Member Access to Zepbound® Vials

April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to […]

Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »

Eli Lilly’s New Weight Loss Pill Shows Promise

News / John LaRosa

April 17, 2025 New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6%

Eli Lilly’s New Weight Loss Pill Shows Promise Read More »

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

News / John LaRosa

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down

News / John LaRosa

March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »

GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits

News / John LaRosa

March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve used a medication like Ozempic, Wegovy or Mounjaro to slim down. That’s a big slice of the population — and new research shows that being on these medications influences what

GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits Read More »

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

News / John LaRosa

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over

News / John LaRosa

Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »

Medifast Reports Q4 and Full Year 2024 Results

News / John LaRosa

Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0

Medifast Reports Q4 and Full Year 2024 Results Read More »

Conflicts in Trump Administration For Support of GLP-1 Meds

Uncategorized / John LaRosa

Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed

Conflicts in Trump Administration For Support of GLP-1 Meds Read More »

The Party Is Almost Over for GLP-1 Compounders

Uncategorized / John LaRosa

January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the

The Party Is Almost Over for GLP-1 Compounders Read More »